Abstract
TO TEST A) ASSOCIATION OF HBA1C % AND THE FREQUENCY OF T2 DIABETIC COMPLICATIONS B) T2 DIABETES TREATMENT (ALGORITHM AACE VS ADA+ EASD REGIME)

Mirza Asif Baig* and Anil K. Sirasgi

ABSTRACT

Background: D.M is a metabolic disorder characterized by the presence of hyperglycemia due to impaired insulin action/sensitivity and β cell defect. India occupies the second position, after China, in the global list of countries with a total of 66.8 million cases. Standardised HbA1C cut off values are taken for the diagnosis, treatment and to assess prognostic outcome of T2 Diabetes. Methods: The cut off HbA1c value ≥6.5% (NSGP standards) is taken as new criteria to diagnose T2 Diabetes and it can be used for predicting the complications. Efficacy of Incretin based therapy (AACE) was compared with other hyopoglycemics (ADA+EASD) as second line of drugs. Results Of the 165 cases of complicated T2 Diabetes 72% of the cases with HbA1C level >7% showed complication like Diabetic retinopathy and microalbuminuria After Rx means patients after receiving hypoglycemic drugs showing improvement in the form of reduced HbA1C, Fasting and PP glucose levels. Out of 155 cases on GLP1 agonist, 120 cases(77.40%) shows considerable reduction in HbA1C% (0.5- 1%)& Of 145 cases on other hypoglycemics, 100 cases (68.9%) reduction of HbA1C % but the average reduction was <0.5% of HbA1C. Conclusion: Studies shows a direct & linear correlation of HbA1C with the diabetic retinopathy and micro-albuminuria. It is very safe to say that HbA1C is better parameter than FBS & 2 hour PP plasma glucose level in diagnosing & predicting the complications of diabetes. The formulations of AACE guidelines for treatment of T2 Diabetes mellitus appears to be better as it in includes weight reduction stratigies, obesity & prediabetes management. GLP1 agonists as 2nd line drugs (AACE) are more effective as compared to other hypoglycemic.

Keywords: Type 2 diabetes, HbA1C, Diabetic retinopathy, Incretin therapy, microalbuminuria.


[Full Text Article]

Login





Forgot Password  |  Register

Indexing

Best Paper Awards

European Journal of Biomedical and Pharmaceutical Sciences (EJBPS) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.

Best Article of current issue :

Tangudu Nagabhusana Rao

Download Article : Click here

News & Updation

  • SEPTEMBER ISSUE PUBLISHED

    SEPTEMBER 2018 Issue has been successfully launched on 1 September 2018

  • EJBPS New Impact Factor

    Its our Pleasure to Inform you that EJBPS Impact Factor has been increased from 4.382 to 4.918 due to high quality Publication at International Level.

  • Index Copernicus Value

    EJBPS Received Index Copernicus Value 77.3, due to High Quality Publication in EJBPS at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in EJBPS coming Issue.

     

UG/PG/Ph.D Research Publication

Research Scholar of UG/PG/Ph.D can Submit their Research Article/Review Article/Case Study/Short Communication for Publication in EJBPS

Downloads

Copyright From

Covering Letter

                        Author Instruction 
 

PLAGERLUM REPORT